Acumen Pharmaceuticals, Inc.
For the period ended Jun 30, 2025. Filed Aug 12, 2025.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Jun 30, 2025 · Filed Aug 12, 2025
ABOS$0.23-3.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Statements of Operations and Comprehensive Loss
(in thousands, except share and per share data)
| Three Months Ended June 30, | Six Months Ended June 30, | |||
|---|---|---|---|---|
| 2025 | 2024 | 2025 | 2024 | |
| Operating expenses | ||||
| Research and development | $37,125 | $19,533 | $62,391 | $31,982 |
| General and administrative | 4,625 | 4,848 | 9,729 | 10,173 |
| Total operating expenses | 41,750 | 24,381 | 72,120 | 42,155 |
| Loss from operations | (41,750) | (24,381) | (72,120) | (42,155) |
| Other income (expense) | ||||
| Interest income | 2,015 | 3,816 | 4,486 | 7,821 |
| Interest expense | (1,046) | (1,004) | (2,069) | (2,004) |
| Change in fair value of embedded derivatives | (40) | 1,100 | 150 | 1,050 |
| Other expense, net | (129) | (68) | (193) | (122) |
| Total other income | 800 | 3,844 | 2,374 | 6,745 |
| Net loss | (40,950) | (20,537) | (69,746) | (35,410) |
| Other comprehensive gain (loss) | ||||
| Unrealized gain (loss) on marketable securities | 8 | (20) | 71 | (476) |
| Comprehensive loss | $(40,942) | $(20,557) | $(69,675) | $(35,886) |
| Net loss per common share, basic and diluted | $(0.68) | $(0.34) | $(1.15) | $(0.59) |
| Weighted-average shares outstanding, basic and diluted | 60,573,425 | 60,079,778 | 60,549,658 | 59,945,889 |
Condensed Statements of Changes in Stockholders’ Equity
(in thousands, except share data)
For the Three Months Ended June 30, 2025
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveIncome (Loss) · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance as of March 31, 2025 | 60,573,425 | $6 | $509,423 | $(353,923) | $15 | $155,521 | |||||
| Unrealized gain on marketable securities | — | — | — | — | 8 | 8 | |||||
| Stock-based compensation | — | — | 2,498 | — | — | 2,498 | |||||
| Net loss | — | — | — | (40,950) | — | (40,950) | |||||
| Balance as of June 30, 2025 | 60,573,425 | $6 | $511,921 | $(394,873) | $23 | $117,077 | |||||
For the Three Months Ended June 30, 2024
| Common Stock · AdditionalPaid-inCapital · AccumulatedDeficit · AccumulatedOtherComprehensiveLoss · TotalStockholders’Equity | |||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares · Amount | |||||||||||
| Balance as of March 31, 2024 | 60,079,778 | $6 | $499,843 | $(237,671) | $(144) | $262,034 | |||||
| Unrealized loss on marketable securities | — | — | — | — | (20) | (20) | |||||
| Stock-based compensation | — | — | 2,470 | — | — | 2,470 | |||||
| Net loss | — | — | — | (20,537) | — | (20,537) | |||||
| Balance as of June 30, 2024 | 60,079,778 | $6 | $502,313 | $(258,208) | $(164) | $243,947 | |||||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.